Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carnitine orotate is a compound formed by combining L-carnitine, an amino acid derivative essential for the transport of long-chain fatty acids into mitochondria for β-oxidation and energy production, with orotic acid, a precursor in nucleic acid biosynthesis. The combination acts synergistically to promote fatty acid metabolism and support liver function. Carnitine orotate is primarily used as a hepatoprotective agent to improve hepatic steatosis (fatty liver), normalize alanine aminotransferase (ALT) levels, and enhance glucose tolerance and insulin sensitivity. It has shown benefits in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), obesity, metabolic syndrome, dyslipidemia, and type 2 diabetes by improving mitochondrial function and reducing oxidative stress in hepatocytes[1][2][4][5][6]. The drug is available under brand names such as Godex DS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carnitine orotate.